在STEC-HUS中治疗心力衰竭的体外膜氧化和eculizumab
Marissa Y Chou1, Eesha Natarajan1, Andrew J Connolly2
1Division of Critical Care, Department of Pediatrics, University of California San Francisco, San Francisco, California.
Pediatrics
|October 15, 2025
概括
严重的Shiga毒素产生大肠杆菌血溶性尿素综合征 (STEC-HUS) 在儿童中进展为心力衰竭,需要体外膜氧化 (ECMO) 和eculizumab治疗. 患者恢复正常的心脏功能和神经结果.
科学领域:
- 儿科脏病学 儿科脏病学
- 关键护理医学 关键护理医学
- 心脏病学 心脏病学
背景情况:
- 血溶性尿性综合征 (HUS) 是滋果毒素产生大肠杆菌 (STEC) 感染的严重并发症.
- STEC-HUS可导致急性功能衰竭和危及生命的外器官损伤,包括心力衰竭和血小板狭窄症.
研究的目的:
- 呈现一种严重的STEC-HUS与心力衰竭的病例,通过体外膜氧化 (ECMO) 和eculizumab进行管理.
- 为了说明ECMO在HUS患者的可行性,患有消耗性血小板缺血症.
- 探索eculizumab在心脏恢复中的潜在作用,并为HUS中ECMO提出抗凝参数.
主要方法:
- 一个2岁男孩的病例报告,患有严重的STEC-HUS和心力衰竭.
- 管理涉及5天的体外膜氧化 (ECMO).
- 治疗包括eculizumab,一种补充成分5抑制剂.
主要成果:
- 患者在正常心脏功能和良好的神经结果下幸存下来.
- 尽管与HUS.相关的消耗性血小板缺血,但ECMO是可行的.
- 在STEC-HUS.US中,eculizumab可能有助于心脏恢复.
结论:
- 这一案例突出了使用ECMO和eculizumab成功治疗心力衰竭的严重STEC-HUS.
- 需要进一步的研究,以了解STEC-HUS中的补充失调,并制定心脏表现的治疗指南.
相关概念视频
Heart Failure VI: Adjunct Therapies
255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
Myocarditis III: Medical Management
174
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
174
Cardiomyopathy V: Interprofessional Care
338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
586
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
586
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
176
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
176
Acute Respiratory Failure-V
455
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
455


